Advertisement

Topics

FDA Expands Approval of Sprycel for Children with Philadelphia Chromosome-Positive CML in Chronic Phase

09:37 EST 10 Nov 2017 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel® (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).1 This approval for Sprycel in pediatric patients with Ph+ CML in chronic phase was granted under priority review, and the …

Original Article: FDA Expands Approval of Sprycel for Children with Philadelphia Chromosome-Positive CML in Chronic Phase

NEXT ARTICLE

More From BioPortfolio on "FDA Expands Approval of Sprycel for Children with Philadelphia Chromosome-Positive CML in Chronic Phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...